4:21 PM
 | 
Jun 04, 2010
 |  BC Extra  |  Clinical News

Roche to present PLX4032 data at ASCO

Roche (SIX:ROG; OTCQX:RHHBY) announced the availability of abstracts slated for presentation at the American Society of Clinical Oncology meeting, including data from three Phase I trials of PLX4032 in patients with V600E BRAF mutations. In 22 metastatic melanoma patients, twice-daily PLX4032 produced an overall response rate (ORR) of 86% as measured...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >